Trends in antimicrobial drug development: implications for the future
- PMID: 15127341
- DOI: 10.1086/420937
Trends in antimicrobial drug development: implications for the future
Abstract
The need for new antimicrobial agents is greater than ever because of the emergence of multidrug resistance in common pathogens, the rapid emergence of new infections, and the potential for use of multidrug-resistant agents in bioweapons. Paradoxically, some pharmaceutical companies have indicated that they are curtailing anti-infective research programs. We evaluated the United States Food and Drug Administration (FDA) databases of approved drugs and the research and development programs of the world's largest pharmaceutical and biotechnology companies to document trends in the development of new antimicrobial agents. FDA approval of new antibacterial agents decreased by 56% over the past 20 years (1998-2002 vs. 1983-1987). Projecting future development, new antibacterial agents constitute 6 of 506 drugs disclosed in the developmental programs of the largest pharmaceutical and biotechnology companies. Despite the critical need for new antimicrobial agents, the development of these agents is declining. Solutions encouraging and facilitating the development of new antimicrobial agents are needed.
Similar articles
-
Antibacterial drug discovery in the 21st century.Clin Microbiol Infect. 2004 Nov;10 Suppl 4:10-7. doi: 10.1111/j.1465-0691.2004.1005.x. Clin Microbiol Infect. 2004. PMID: 15522035 Review.
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Antimicrobial drug development--the past, the present, and the future.Clin Microbiol Infect. 2004 Nov;10 Suppl 4:23-31. doi: 10.1111/j.1465-0691.2004.1007.x. Clin Microbiol Infect. 2004. PMID: 15522037 Review.
-
Antibacterial drug discovery: is it all downhill from here?Clin Microbiol Infect. 2004 Nov;10 Suppl 4:18-22. doi: 10.1111/j.1465-0691.2004.1006.x. Clin Microbiol Infect. 2004. PMID: 15522036 Review.
-
Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.Infection. 2007 Jun;35(3):167-74. doi: 10.1007/s15010-007-6269-7. Infection. 2007. PMID: 17565458
Cited by 158 articles
-
Broad spectrum antimicrobial activities from spore-forming bacteria isolated from the Vietnam Sea.PeerJ. 2020 Oct 16;8:e10117. doi: 10.7717/peerj.10117. eCollection 2020. PeerJ. 2020. PMID: 33088622 Free PMC article.
-
Lasso Peptide Microcin J25 Effectively Enhances Gut Barrier Function and Modulates Inflammatory Response in an Enterotoxigenic Escherichia coli-Challenged Mouse Model.Int J Mol Sci. 2020 Sep 5;21(18):6500. doi: 10.3390/ijms21186500. Int J Mol Sci. 2020. PMID: 32899529 Free PMC article.
-
Plant-Based Phytochemicals as Possible Alternative to Antibiotics in Combating Bacterial Drug Resistance.Antibiotics (Basel). 2020 Aug 4;9(8):480. doi: 10.3390/antibiotics9080480. Antibiotics (Basel). 2020. PMID: 32759771 Free PMC article. Review.
-
Evaluation of Antibiotic Utilization in an Emergency Department After Implementation of an Antimicrobial Stewardship Pharmacist Culture Review Service.Hosp Pharm. 2020 Aug;55(4):261-267. doi: 10.1177/0018578719844171. Epub 2019 Apr 22. Hosp Pharm. 2020. PMID: 32742015
-
The Revaluation of Plant-Derived Terpenes to Fight Antibiotic-Resistant Infections.Antibiotics (Basel). 2020 Jun 13;9(6):325. doi: 10.3390/antibiotics9060325. Antibiotics (Basel). 2020. PMID: 32545761 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
